Savcic M, Hauert J, Bachmann F, Wyld P J, Geudelin B, Cariou R
Department of Internal Medicine, CHUV, Lausanne, Switzerland.
Semin Thromb Hemost. 1999;25 Suppl 2:15-9.
Clopidogrel, a potent novel platelet ADP-receptor antagonist, induces a significant inhibition of ADP-induced platelet aggregation. Maximum inhibition of 40 to 50% is observed 2 to 5 hours after a single 400 mg dose. The same level of inhibition is achieved with 75 mg once daily at steady state, i.e., after 3 to 7 days of repeated dosing. Based on these data, two studies were undertaken to investigate whether a treatment regimen comprising a large initial dose (loading dose) of clopidogrel, followed by daily doses of 75 mg, might provide a sustained steady-state level of inhibition of platelet aggregation induced by 5 microM of ADP within hours after first dosing. In one study, 10 healthy male subjects received a 375 mg loading dose of clopidogrel on day 1, then daily doses of 75 mg from day 2 to day 10. Mean inhibition of platelet aggregation, already significant at 30 minutes, reached 55+/-8.2% (+/-SEM) at 60 minutes, and a maximum of 80+/-3.6% at 5 hours. No further significant change was observed between 5 hours and 24 hours, and from day 2 through day 10 with subsequent daily doses of 75 mg. In the second study, conducted according to a randomized, single-blind design, four parallel treatment groups of nine healthy male subjects received a loading dose of 75 mg, 150 mg, 225 mg, or 300 mg of clopidogrel on day 1, respectively, and 75 mg once daily from day 2 to day 5. Mean (+/-SD) inhibition of platelet aggregation over the 2 to 24 hours post-loading dose period was 22+/-14.5%, 21+/-13.4%, 35+/-20.6% and 31+/-13.3%, respectively. On day 5, it was 48+/-14.7%, 33 +/-14.1%, 51+/-15.7% and 40+/-10.9% for the 75, 150, 225 and 300 mg loading dose groups, respectively. The smallest day 1 to day 5 difference was observed for the 300 mg group and the largest for the 75 mg group, indicating that the development of the full inhibitory effect of clopidogrel was faster with the loading doses higher than with 75 mg, and fastest with the 300 mg loading dose. These data and those of previous studies indicate that a dose of 300 to 400 mg produces a rapid onset of the pharmacodynamic action of clopidogrel, with levels of inhibition close to steady-state reached within 2 hours.
氯吡格雷是一种新型强效血小板 ADP 受体拮抗剂,能显著抑制 ADP 诱导的血小板聚集。单次服用 400mg 剂量后 2 至 5 小时,可观察到最大抑制率达 40%至 50%。在稳态时,即重复给药 3 至 7 天后,每日服用 75mg 可达到相同的抑制水平。基于这些数据,开展了两项研究,以调查一种治疗方案,即先给予氯吡格雷大剂量初始剂量(负荷剂量),随后每日服用 75mg,是否能在首次给药后数小时内使血小板聚集受到的抑制维持在稳态水平。在一项研究中,10 名健康男性受试者在第 1 天接受 375mg 氯吡格雷负荷剂量,然后从第 2 天至第 10 天每日服用 75mg。血小板聚集的平均抑制率在 30 分钟时已显著,60 分钟时达到 55±8.2%(±SEM),5 小时时最大为 80±3.6%。在 5 小时至 24 小时之间以及从第 2 天至第 10 天每日服用 75mg 后,未观察到进一步的显著变化。在第二项研究中,按照随机、单盲设计,四个由 9 名健康男性受试者组成的平行治疗组在第 1 天分别接受 75mg、150mg、225mg 或 300mg 氯吡格雷的负荷剂量,并从第 2 天至第 5 天每日服用 75mg。负荷剂量后 2 至 24 小时期间血小板聚集的平均(±SD)抑制率分别为 22±14.5%、21±13.4%、35±20.6%和 31±13.3%。在第 5 天,75mg、150mg、225mg 和 300mg 负荷剂量组的抑制率分别为 48±14.7%、33±14.1%、51±15.7%和 40±10.9%。300mg 组在第 1 天至第 5 天的差异最小,75mg 组最大,这表明负荷剂量高于 75mg 时,氯吡格雷的完全抑制作用起效更快,300mg 负荷剂量时最快。这些数据以及先前研究的数据表明,300 至 400mg 的剂量可使氯吡格雷的药效作用迅速起效,2 小时内抑制水平接近稳态。